

## MESSAGE FROM THE ACTING COMMISSIONER



I am pleased to present the Food and Drug Administration's (FDA) FY 2007 Congressional Justification. FDA is the oldest consumer protection agency, and on June 30, 2006, we will celebrate 100 years of service to the nation.

FDA's performance budget request continues support for the President's and Secretary's public health priorities and reflects the goals and objectives in the Department's FY 2005 – 2010 Strategic Plan. Our justification includes the FY 2007 Annual Performance Plan and the FY 2005 Annual Performance Report, as required by the Government Performance and Results Act of 1993.


The FDA budget justification directly links the presentation of the proposed budget with our performance. At FDA, we manage our programs to achieve measurable results toward objectives that protect and advance the public health. We are eager to share with Congress and the American public our progress on four strategic goals:

- Increasing access to innovative products and technologies to improve health.
- Enhancing patient and consumer protection and empowering them with better information about regulated products.
- Improving product quality, safety, and availability through better manufacturing and product oversight.
- Transforming FDA business operations, systems, and infrastructure to support FDA's mission in the 21<sup>st</sup> Century.

FDA's strategy will enable us to deploy our resources wisely to achieve our vital public health mission: assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices and our nation's food supply.

With the FY 2007 performance budget request, FDA begins our second century of service. As we reflect on the past century, we are struck by the pace of health care innovation. Looking forward, we recognize that scientific discovery will transform food and medical product development at a more dynamic and breathtaking pace.

FDA pledges to respond to this transformation. We will help speed innovations that make our food supply safer and make medicines more effective, safer, and more affordable. We will also work to ensure that the public receives the accurate, science-based information they need to use medicines and foods to improve their health. FDA will meet these challenges while maintaining its century-old commitment to the principles that have made us the world's "gold standard" for regulating food and medical products. We have designed our FY 2007 budget to achieve these important goals.

  
Andrew C. von Eschenbach, M.D.

BLANK PAGE

# Food and Drug Administration

## FY 2007 Congressional Budget Request

### Table of Contents

|   | <u>Page</u> |
|---|-------------|
| Letter from the Acting Commissioner                       | i           |
| Table of Contents   | iii         |
| Organizational Chart                                      | vii         |
| <br>  |             |
| <b><u>Performance Budget in Brief</u></b>                 |             |
| Performance Budget Overview                               | 1           |
| Statement of FDA Mission                                  | 2           |
| FDA Strategic Plan  | 3           |
| Overview of FDA Performance                               | 7           |
| PART Summary Table (FY 2005 – FY 2007)                    | 8           |
| Overview of FDA’s Budget Request                          | 9           |
| Pandemic Preparedness                                     | 13          |
| Food Defense  | 19          |
| Critical Path to Personalized Medicine                    | 23          |
| Improved Drug Safety                                      | 27          |
| Human Tissues   | 30          |
| Funding for MDUFMA and ADUFA Triggers                     | 33          |
| Cost of Living Pay Increase                               | 37          |
| Unified Financial Management System (UFMS)                | 40          |
| Infrastructure to Support Critical Agency Operations      | 42          |
| FDA Strategic Redeployment                                | 45          |
| Current Law User Fee Increases                            | 48          |
| Food and Animal Feed Export Certification User Fee        | 53          |
| Reinspection User Fee                                     | 55          |
| FDA’s Implementation of the President’s Management Agenda | 57          |
| Appropriation Language and Analysis                       | 68          |
| Summary of Base Resources                                 | 73          |
| Summary of Changes  | 74          |
| Crosswalk to Summary of Changes:                          |             |
| Budget Authority  | 75          |
| User Fees   | 76          |
| Program Level, page 1                                     | 77          |
| Program Level, page 2                                     | 78          |
| All Purpose Tables  |             |
| Budget Authority  | 79          |
| User Fees   | 80          |
| Program Level   | 81          |
| <br>  |             |
| <b><u>Narratives by Activity</u></b>                      |             |
| Foods   | 83          |
| Human Drugs   | 115         |
| Office of Orphan Products Development                     | 145         |

# Food and Drug Administration

## FY 2007 Congressional Budget Request

### Table of Contents

| <b><u>Narratives by Activity, continued</u></b>  | <b>Page</b> |
|--|-------------|
| Biologics  | 153         |
| Animal Drugs and Feeds   | 177         |
| Devices and Radiological Health  | 203         |
| National Center for Toxicological Research   | 233         |
| Field Activities - Office of Regulatory Affairs  | 245         |
| Other Activities   | 279         |
| Infrastructure   | 299         |
| Buildings and Facilities   | 307         |
| <br>   |             |
| <b><u>Performance Detail</u></b>   |             |
| Detail of Performance Analysis   |             |
| Foods Performance Goals  | 311         |
| Human Drugs Performance Goals  | 327         |
| Biologics Performance Goals  | 345         |
| Animal Drugs and Feeds Performance Goals   | 351         |
| Medical Devices Performance Goals  | 355         |
| National Center for Toxicological Research Performance Goals   | 367         |
| Combined ORA Performance Goals**   | 375         |
| Other Activities Performance Goals   | 391         |
| Summary of Measures and Results  | 397         |
| Changes and Improvement over Previous Years  | 399         |
| <br>   |             |
| <b><u>Exhibits</u></b>   |             |
| Object Class Distribution  |             |
| Budget Authority   | 407         |
| User Fees  | 408         |
| Program Level  | 409         |
| Salaries and Expenses – Budget Authority   | 410         |
| Functional Activity Tables   | 411         |
| Unified Financial Management System, Accounting Operations, and<br>Automating Administrative Systems | 417         |
| Extramural Research Funding by State and Recipients  | 418         |
| Significant Items in Appropriations Committee Reports  | 420         |
| HIV/AIDS Resource Funding  | 452         |
| Authorizing Legislation  | 453         |
| Appropriations History Tables  | 455         |
| Detail of Full-Time Equivalent Employment  | 461         |
| Detail of FTE by Grade   | 462         |
| New Positions Requested  | 463         |

\*\* This section is provided for illustrative purposes only. The field performance goals are listed with the appropriate program sections as well.

# Food and Drug Administration

## FY 2007 Congressional Budget Request

### Table of Contents

|   | <b>Page</b> |
|---|-------------|
| <b><u>Exhibits, continued</u></b>           |             |
| Geographic Distribution of Facilities       | 466         |
| User Fee History                            | 472         |
| DHHS Charges and Assessments                | 473         |
| Anticipated Consolidations Impacting on FDA | 478         |
| Sources of Funding from Other Agencies      | 479         |
| Summary of Full Costs                       | 480         |
| Glossary of Acronyms                        | 485         |
| <br>  |             |
| <b><u>States Fact Sheets</u></b>            |             |
| State Fact Sheets                           | 493         |

BLANK PAGE

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## FOOD AND DRUG ADMINISTRATION

Main Tel: (301) 827-2410  
 Fax: (301) 443-3100  
 Parklawn Bldg.  
 Mail Code: HF-1  
 5600 Fishers Lane  
 Rockville, MD 20857

**OFFICE OF THE COMMISSIONER**  
**COMMISSIONER OF FOOD AND DRUGS**  
 Andrew C. von Eschenbach, M.D. (Acting)  
**DEPUTY COMMISSIONER FOR POLICY**  
 Scott Gottlieb, M.D.  
**DEPUTY COMMISSIONER FOR OPERATIONS**  
 Janet Woodcock, M.D.  
**DEPUTY COMMISSIONER FOR INTERNATIONAL AND SPECIAL PROGRAMS**  
 Murray M. Lumpkin, M.D. (DA)

**OFFICE OF EQUAL EMPLOYMENT OPPORTUNITY AND DIVERSITY MANAGEMENT**  
**DIRECTOR**  
 Georgia Coffey (DAJDC)

**OFFICE OF THE ADMINISTRATIVE LAW JUDGE**  
**ADMINISTRATIVE LAW JUDGE**  
 Daniel J. Davidson (DAD)

**OFFICE OF THE CHIEF COUNSEL**  
**CHIEF COUNSEL**  
 Sheldon Bradshaw, J.D. (DAA)

**OFFICE OF EXTERNAL RELATIONS**  
**ASSOCIATE COMMISSIONER**  
 Jason D. Brodsky (Acting) (DAE)

**OFFICE OF LEGISLATION**  
**ASSOCIATE COMMISSIONER**  
 Patrick Roman (DAN)

**OFFICE OF CRISIS MANAGEMENT**  
**DIRECTOR**  
 Ellen F. Morrison (DAP)

**OFFICE OF MANAGEMENT**  
**ASSOCIATE COMMISSIONER**  
 Kathleen Heuer (DAJ)

**OFFICE OF SCIENCE AND HEALTH COORDINATION**  
**ASSOCIATE COMMISSIONER**  
 Norris E. Alderson, Ph.D. (DAK)

**OFFICE OF INTERNATIONAL ACTIVITIES AND STRATEGIC INITIATIVES**  
**DEPUTY COMMISSIONER**  
 Murray M. Lumpkin, M.D. (DAL)

**OFFICE OF POLICY AND PLANNING**  
**ASSOCIATE COMMISSIONER**  
 Randall Lutter, Ph.D. (DAH)

**OFFICE OF REGULATORY AFFAIRS**  
**ASSOCIATE COMMISSIONER**  
 Margaret Glavin (DBR)

**CENTER FOR FOOD SAFETY AND APPLIED NUTRITION**  
**DIRECTOR**  
 Robert E. Brackett, Ph.D. (DBF)

**CENTER FOR DRUG EVALUATION AND RESEARCH**  
**DIRECTOR**  
 Steven Galson, M.D. (DBN)

**CENTER FOR VETERINARY MEDICINE**  
**DIRECTOR**  
 Stephen F. Sundlof, D.V.M., Ph.D. (DBV)

**CENTER FOR DEVICES AND RADIOLOGICAL HEALTH**  
**DIRECTOR**  
 Daniel G. Schultz, M.D. (DBV)

**NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH**  
**DIRECTOR**  
 William Slikker, Jr., Ph.D. (Acting) (DT)

**CENTER FOR BIOLOGICS EVALUATION AND RESEARCH**  
**DIRECTOR**  
 Jesse Goodman, M.D. (DBB)

BLANK PAGE